Mumbai: Drug maker Zydus Cadila said it has received World Health Organisation’s (WHO) approval to sell rabies vaccine — Lyssavac N — to UN agencies.
The vaccine would be available to various United Nations agencies and with this Zydus Cadila has become the first Indian company and the second in the world to receive the said approval, Cadila Healthcare said in filing to the Bombay Stock Exchange (BSE).
Cadila Healthcare is the flagship company of Zydus Cadila Group. The group produces three million doses of the vaccine per annum.
The vaccine is marketed in India under the brand name Vaxirab. The facility was set up in Ahmadabad in collaboration with Switzerland-based Berna Biotech, the company said.
The vaccine is currently exported to South Asia and Africa, the filing said.
Rabies virus infects the central nervous system, causing disease in the brain and subsequently death.
Shares of the company were trading at Rs286.50, up 0.23% in the afternoon trade on the BSE.